Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
-
Shares outstanding
-
266,212,950
-
Total 13F shares
-
50,705,958
-
Share change
-
-2,116,600
-
Total reported value
-
$143,501,265
-
Price per share
-
$2.83
-
Number of holders
-
55
-
Value change
-
-$7,116,223
-
Number of buys
-
23
-
Number of sells
-
25
Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) as of Q2 2022
As of 30 Jun 2022,
Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,705,958 shares.
The largest 10 holders included
Blackstone Inc., Syncona Portfolio Ltd, Nantahala Capital Management, LLC, Frazier Life Sciences Management, L.P., TFG Asset Management GP Ltd, CITADEL ADVISORS LLC, SCHRODER INVESTMENT MANAGEMENT GROUP, Pendal Group Ltd, Woodline Partners LP, and Alphabet Inc..
This page lists
56
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.